CATXHIGH SIGNALFINANCIAL10-K

CATX shows severe cash burn acceleration with operating cash flow deteriorating 351% to -$82.5M while cash reserves depleted by half to $30.6M, creating potential liquidity concerns.

The company is burning through cash at an unsustainable rate, with operating cash flow worsening dramatically from -$18.3M to -$82.5M, primarily driven by R&D expenses doubling to $84.2M. With cash reserves falling 50% to just $30.6M and current liabilities increasing 57%, CATX faces potential funding pressures that could require immediate capital raising or strategic alternatives.

Comparing 2026-03-16 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

CATX exhibits classic biotech cash burn patterns but at an alarming accelerated pace, with R&D expenses more than doubling to $84.2M driving the 351% deterioration in operating cash flow to -$82.5M. The company's financial cushion has significantly eroded with cash falling 50% to $30.6M while current liabilities jumped 57% to $28.7M, and stockholders' equity declined 29% to $207M. This financial trajectory suggests CATX is rapidly consuming capital for drug development but faces mounting liquidity pressure that may necessitate near-term financing.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-350.9%
-$18.3M→-$82.5M

Operating cash flow fell 350.9% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+102.3%
$41.6M→$84.2M

R&D investment increased 102.3% — signals commitment to future product development, though near-term margin impact.

Accounts Receivable
Balance Sheet
-94.8%
$116K→$6K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-76.6%
$54.4M→$12.7M

Capex reduced 76.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
+57.3%
$18.2M→$28.7M

Current liabilities surged 57.3% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-50.3%
$61.6M→$30.6M

Cash declined 50.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Inventory
Balance Sheet
+42.4%
$980K→$1.4M

Inventory surged 42.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
-35.8%
$231.2M→$148.4M

Current assets declined 35.8% — monitor working capital adequacy and short-term liquidity.

Net Income
P&L
-30.1%
-$79.3M→-$103.1M

Net income declined 30.1% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-28.8%
$290.7M→$207.0M

Equity decreased 28.8% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-26
ADDED
and international trade policies, including tariffs, on our costs for supplies, equipment and materials used in the development and production of our targeted alpha therapy drug product candidates; and expectations, beliefs, intentions and strategies regarding the future.
Disruptions at the FDA, including due to a lapse in appropriations and/or decreased funding for the FDA, could prevent the FDA from performing functions on which our business relies, which could negatively impact our business.
We receive federal funding to conduct certain research on our product candidates and other programs, and recent federal policy changes could disrupt that funding.
If we are unable to execute our sales and marketing strategy for our product candidates, if commercialized, and are unable to gain market acceptance, we may be unable to generate sufficient revenue to sustain our business.
We may rely partially on third parties to manufacture our clinical pharmaceutical supplies and could continue to rely on third parties to produce commercial supplies of any approved product candidate, and our dependence on third party suppliers could adversely impact our business.
+7 more — sign up free →
REMOVED
These statements are based on certain assumptions and analyses made by us in light of our experience and our assessment of historical trends, current conditions and expected future developments as well as other factors we believe are appropriate under the circumstances.
AVAILABLE INFORMATION As soon as reasonably practicable after they are filed electronically with the SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, other SEC filings and amendments to those reports are available without charge on our website, www.perspectivetherapeutics.com, which we also use to announce material information to the public.
We are providing the address to our website solely for the information of investors.
We do not intend the address to be an active link or to otherwise incorporate the contents of the website into this Form 10-K.
SUMMARY OF RISK FACTORS Investing in our common stock involves significant risks.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →